利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

86 条记录 (耗时 0.039 秒)

    Piperazine derivatives, their preparation and uses in therapy
    18.
    发明授权
    Piperazine derivatives, their preparation and uses in therapy 失效

    公开(公告)号：US07109201B2

    公开(公告)日：2006-09-19

    申请号：US10471433

    申请日：2002-03-11

    申请人： Mervyn Thompson ,  Paul Adrian Wyman

    发明人： Mervyn Thompson ,  Paul Adrian Wyman

    IPC分类号： A61K31/496 ,  C07D403/04 ,  C07D401/14

    CPC分类号： C07D401/10 ,  C07D209/08

    摘要： Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: in which Ra is a group of formula (i) wherein P2 is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring; P3 is phenyl, naphthyl or heteroaryl; R1 is NR4COR5, NR4SO2R5, CH2NR4SO2R5, CH2NR4COR5 or CH2NR4CO2R5 where R4 and R5 are independently hydrogen or C1-6alkyl; R2 and R3 are independently halogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, COC1-6alkyl, haloC1-6alkyl, cyano or NR6R7 where R6 and R7 are independently hydrogen or C1-6alkyl; b and c are independently 0, 1, 2 or 3; Y is a single bond, CH2 or NH; W is —(CR9R10)t—where t is 2, 3 or 4 and R9 and R10 are independently hydrogen or C1-6alkyl or W is a group CH═CH; Rb is hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, COC1-6alkyl, cyano or C1-6alkoxy; and Rc is hydrogen or C1-6alkyl. Processes for preparation of the compounds and their uses in therapy, particularly depression, are also disclosed.

    Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
    20.
    发明授权
    Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity 失效
    具有抗惊厥活性的四氢萘并吡喃基甲酰胺

    公开(公告)号：US06410555B1

    公开(公告)日：2002-06-25

    申请号：US09719335

    申请日：2001-02-16

    申请人： John David Harling ,  Frank Peter Harrington ,  Mervyn Thompson

    发明人： John David Harling ,  Frank Peter Harrington ,  Mervyn Thompson

    IPC分类号： A61K31435

    CPC分类号： C07D471/04 ,  C07D471/10

    摘要： Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where R1 is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6alkynyl; R2 is hydrogen or, up to three substituents selected from halogen, NO2, CN, N3, CF3O—, CF3S—, CF3SO2—, CF3CO—, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkyl, C1-6alkylCO—, C3-6cycloalkylO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS—, C1-6alkylSO2—, (C1-4alkyl)2NSO2—, (C1-4alkyl)NHSO2—, (C1-4alkyl)2NCO—, (C1-4alkyl)NHCO— or CONH2; or —NR5R6 where R5 is hydrogen or C1-4alkyl, and R6 is hydrogen, C1-4alkyl, formyl, —CO2C1-4alkyl or —COC1-4alkyl; or two R2 groups together form a carbocyclic ring that is saturated or unsaturated, optionally interrupted by O or NH; R3 groups and R4 groups are each independently hydrogen or C1-6alkyl and/or the two R3 groups and/or the two R4 groups together form a C3-6spiroalkyl group, provided that at least one R3 or R4 group is not hydrogen; and X is selected from hydrogen, halogen, cyano, alkyl and alkoxy, are useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.

    摘要翻译： 式（I）化合物及其药学上可接受的盐和溶剂化物：其中R 1是氢，C 1-6烷基（任选被羟基或C 1-4烷氧基取代），苯基-C 1-4烷基 - ，C 1-6烯基，C 1-6炔基; R2是氢或最多三个选自卤素，NO 2，CN，N 3，CF 3 O-，CF 3 S-，CF 3 SO 2 - ，CF 3 CO-，C 1-6烷基，C 1-6烯基，C 1-6炔基，C 1-6全氟烷基，C 3-6环烷基 ，C 3-6环烷基-C 1-4烷基 - ，C 1-6烷基，C 1-6烷基CO-，C 3-6环烷基O-，C 3-6环烷基CO-，C 3-6环烷基-C 1-4烷基O - ，C 3-6环烷基-C 1-4烷基CO-，苯基，苯氧基 ，（C 1-4烷基）2 NSO 2 - ，（C 1-4烷基）NHSO 2 - ，（C 1-4烷基）2 NCO - ，（C 1-4烷基），C 1-4烷基 ）NHCO-或CONH 2; 或-NR5R6，其中R5是氢或C1-4烷基，R6是氢，C1-4烷基，甲酰基，-CO2C1-4烷基或-COC1-4烷基; 或两个R 2基团一起形成饱和或不饱和的碳环，任选被O或NH中断; R 3基团和R 4基团各自独立地为氢或C 1-6烷基和/或两个R 3基团和/或两个R 4基团一起形成C 3-6螺环烷基，条件是至少一个R 3或R 4基团不是氢; X选自氢，卤素，氰基，烷基和烷氧基